Hochdosis-Therapie mit Fluconazol 800 mg/die. Literaturübersicht High dose therapy with fluconazole 800 mg/day. Review

Mycoses, Supplement

Volumn 40, Issue 1, 1997, Pages 33-42

  Pcnk, A ^a   Pittrow, L ^a  

^a PFIZER INC   (United States)

Author keywords

Candidemia; Cryptococcal meningitis; Endemic mcoses; Fluconazole; High dose therapy 800 mg day; Non neutropenic patients; Oropharyngeal candidosis

Indexed keywords

FLUCONAZOLE; ANTIFUNGAL AGENT;

CANDIDA; CANDIDIASIS; COCCIDIOIDES IMMITIS; CONFERENCE PAPER; CRYPTOCOCCUS NEOFORMANS; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FUNGAL MENINGITIS; HUMAN; MYCOSIS; PRIORITY JOURNAL; AIDS RELATED COMPLEX; CRYPTOCOCCAL MENINGITIS; DOSE RESPONSE; MICROBIOLOGY; REVIEW; THRUSH;

CANDIDA; COCCIDIOIDES IMMITIS; FILOBASIDIELLA NEOFORMANS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDIASIS; CANDIDIASIS, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUCONAZOLE; HUMANS; MENINGITIS, CRYPTOCOCCAL; MYCOSES;

EID: 0030657689     PISSN: 09437312     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Pfaller M, Wenzel, R. (1992): Impact of the changing epidemiology of fungal infections in the 1990s EurJ Clin Mtcrobiol Infect Dis 11, 287-291.
2. Jams WR, Marione WJ (1991): Predominant pathogens in hospital infections., /Anlimicrob Chemother 28 (Suppl. A), 15-19
3. Beck-Sague C.Jarvis WR (1993): Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990J/;//flu 167, 1247-1251.
4. Banerjee SX, Emori TG, CuKer DH, Gaynes RRJarvis vVR, Horan T ( 1991): Secular trends in nosocomial primär)' bloodstream infections in the United States, 1980-1989.mJ.U
5. Wey SB, Mori M, Pfaller .vIA, Woolson RF, Wenzel RP (1988): Hospital-acquired candidemia. The attributable mortality and excess length of stay./lrrA Inlern Med 148, 2642-2645.
6. We SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1989): Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Inlern Med 149, 2349-2353.
7. Frazer VJJones M, DunkelJ et al (1992): Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clm Infect Dis 15, 414-421.
8. Walsh TF, Pizzo PA.(1988): vosocomial fungal infections: a classification for hospital-acquired infections and mjcoses arising from endogenous flora or reactKation. Ann Rev Microhol 42, 517-545.
9. Wenzel, R (1995): Nosocomial Candidemia: Risk Factors and Attributable Mortality. Clm Infect Da 20, 1531-1534.
10. Graninger W, Presteril E, Schnee eiss B, Teleky B, Georgopoulos A (1993): Treatment of Candida albicans fungemiauith fluconazole. JInfect 26, 133-146.
11. GraybillJR (1994): Is there a correlation between serum antifungal drug concentration and clinical outcome?J Infect 28 (Suppl. 1), 17-24.
12. Anaissie EJ, Kontoiannis DP, Huis G, Vartivarian SE, Karl C, Prince RA, Bosso J, Bode) GP (1995): Safety, plasma concentrations, and efficacy of high-dose fluconazole in imasive mold infections. J Infect Dis 172, 599-602.
13. National Committee for Clinical Laborator) Standards. Reference method for broth dilution antifungal susceptibility testing of ) easts; proposed standard M27-T (1995): In: National Committee for Clinical Laboratory Standards Wayne, Philadelphia
14. RexJH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laborator) Standards (1997) Development of Interprétée Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Anal)sis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections. Clin Infect Dis 24, 235-247.
15. NCCLS Subcommittee on Antifungal Susceptibility Tests: Summar) minutes on the Open meeting heldjune 1, 1996inRestonVA (unpublished).
16. Pittrow L, Penk A (1996): Plasma- und Gewebekonzentrationen von Fluconazol: Diskussion der Breakpoint-Problematik. Mj cases 39 (Suppl. 2), 58-65.
17. Phillips P, Shafran S, Garber G, Rotstem C, Smaill F, Williams K, Singer J, loannou S and the Canadian Candidemia Stud) Group (1995): Fluconazole versus Amphotericin B for Candidemia in Non-neutropenic Patients: A Multicenter Randomized Trial. Poster LM20, 35. ICAAC, San Francisco.
18. Ngu)en MH, Peacock JE, Tanner DC, Morris AJ, Nguyen ML, Sn)dman DR, Wagener MM, Yu VL (1995): Therapeutic approaches in patients with candidemia. Arch Intern Med 155, 2429-2435.
19. He X, Tiballi RN, Zarins LT, Bradley SF, SangeorzanJA, Kauffman CA (1994): Azole Resistance in Oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Anlimimb Agents Chemother 38, 2495-2497.
20. SangeorzanJA, Bradle) SF, He X, Zarins LT, Ridenour GL, Tiballi RN, Kauffman CA (1994): Epidemiolog) of oral candidiasis in HrV-infected patients: colonization, infection, treatment and emergence of fluconazole resistance. Am J Med 97, 339-346.
21. Pagani JL, Chave JP, Iten A, Durussel C, Bille J, Glauser MP (1996): Traitement par doses croissantes de la candidose oropharyngée resistant au fluconazole. Schxeiz Med IVochenschr 126 (Suppl. 74/11), 495
22. Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, RhincChalbergJ, Pfaller M (1991): Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by In Vitro Susceptibility Testing and DXA Subtype Anal) sis. Clin Infect Dis 18, 240-242.
23. Silling G, Fegeier W, Roos N, Schomaker R, Essink M, Buchner T (1997): Early empiric treatment of infections in neutropenic patients comparing fluconazole with amphotericm B/5-Flucytosine. Acute leukemias VI prognostic factors and treatment strategies, Buchner et al. (eds) Springer-Verlag Berlin Heidelberg p 489-493.
24. Kunzelmann V, Tietz HJ, Roner D, Czaika V, Hopp M, Schmalreck A, Sterry W (1996): Voraussetzungen für eine effcktive Therapie chronisch rezidivierender Vaginalcandidosen. Mjcoses 39 (Suppl. l), 65-72.
25. McLachlan AJ, Tett SE (1996): Pharmacokinetics of fluconazole in people with HIV infection: a population anal)sis. BrJ Clin Pharmaco/41, 291-298.
26. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentr) LO, Williams T, Kontoyiannis DP, Karl CI, Bodey GP (1996): Management of imasKe candidal infections: results of a prospectée, randomized, multicenter study of fluconazole versus amphotericin B and renew of the literature. Clin Infect Dis 23, 964-972.
27. British Society for Antimicrobial Chemotherap) Working Party (1991): Management of deep Candida infection in surgical and intensive care unit patients Intensité Care Med 20, 522-528.
28. Anaissie E, SolomkinJS (1994): Algorithm and Explanation: Approach to the surgical patient at risk for candidiasis. Infection IX, Chapter 10: Fungal Infection, Scientific American, Inc.
29. Abi-Said D, Varlivarian SE, Bodey GP, Anaissie E (1995): Hematogenons Candidiasis: A review of therapeutic studies of fluconazole
30. and amphotericin B and recommendations for management., /Mj, 'col Med 5, 217-224.
31. Meer RD (1991): Treatment of Fungal Infections in Patients vvitli HlV-Infection or AIDS. Ztl. Dad. 281, 1-7.
32. Meer P, Adam D, Hiddemann W, Link H, Maschmever G, HelmerkingM (1992): Intenentionsthcrapic von Infektionen und Fieber unklarer Genese bei neutropenischen Patienten mit malignen hamatologischen Grunderkrankungen. Zeilschr Anlimicrob Antineoplast Chemolher 10, 1-27.
33. Johnson EM, vVarnock DvV (1995): Azole drug resistance in yeasts. JAntwncrob Chemolher 36, 751-755.
34. vvarnock DvV (1996): Azole resistance in easlsj/n/fc/ 32, 93.
35. Presterl E, Lanigg A, Willinger B, Graninger W ( 199G): CandidaInfektioncn in der Intensivmedizin Anaeslliesist 45, 195-210.
36. Berr AJ, Rinaldi MG, GrajbillJR (1992): Use of high-dose fluconazole as saKage therapy for cryptococcal meningitis in patients with AIDS Antinacrob Agents Chemolher 36, 690-692.
37. Haubrich RH, Haghighat D, Bozzette SA, TillesJ, McCutchanJA and thé California Collaborative Treatment Group (1994): Highdose fluconazole for treatment ofcryptococcal disease in patients with human immunodeficiency virus infection., /Infect Dis 170, 238 bis 242.
38. Menichetti F, Fiorio M, Tosti A, Gatti G, Pasticci MB, Miletich F, Marroni M, Bassetti D, Pauluzzi S (1996): High-dose fluconazole therap) for cryplococcal meningitis in patients with AIDS Clm Infect Dis 22, 838-40.
39. Milefchik E, Leal M, Haubrich RH, Haghighat D, Bozzette SA, Larsen RA : High dose fluconazole with and without fluqtosine for AIDS associated cryptococcal meningitis. vvS-B12-5, 9. International Conference on AIDS.June 7-11, 1993, Berlin, Germany.
40. Larsen RA.: Combination therap) for cryptococcosis and speculations for future therapy V3, Conference Crjptococcus & Cryptococcosis, September 22-26, 1996, Paris, France.
41. Paugam A, Dupou)-Camet J, Blanche P, Gangneuv JP, TourteSchaefer C, Sicard D (1991): Increased fluconazole resistance of Cyptococcusneoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 19, 975-976.
42. Sitbon O, Fourme T, Bouree P, Du Pasquier L, Salmeron S (1993): Successful treatment of disseminated cryptococcosis with highdose oral fluconazole./1/DS 7, 1685-1687.
43. Tomberlm MG, Baingana G, Grant R, Mbidde EK, Sande MA : Fluconazole with and uithout flucytosine for AIDS related cryptococcal meningitis in Uganda. Abstr.M71, 34 ICAAC, 1994, Orlando, USA
44. Marriott DJE.: Long-term high dose fluconazole as salvage therapy for AIDS related cryptococcal meningitis: clinical and autopsy findings. Cryptococcosis Meeting, 1993, Mailand, Italien
45. Pappas PG, Hamill RJ, Kauffman CA, Bradsher RvV, McKinsey DS, Cloud GW, Dismukes vVE (1996). Treatment of cryptococcal meningitis in non-HIV infected patients -A randomized comparativ e trial. Clm Infect Dis 23, 873.
46. Just-XubIing G (1994): Die Therapie der Candidose und Crypt ococcose bei AIDS. Mjcoses 37 (Suppl. 2), 56-63.
47. Larsen RA, Bozzette SA, Jones BE (1994): Fluconazole combined with flucjtosine for treatment of cryptococcal meningitis in patients with AIDS. Clm Infect Dis 19, 741-745.
48. Bozzette SA, Larsen RA, ChiuJ, Leal MA, JacobscnJ, Rothman P (1991): A placebo-controlled trial of maintenance therapy with fluconazole after treatment of crjptococcal meningitis in the acquired immunodeficiency S)ndrome. XEnglJ Med 324, 580-584.
49. PowderI) vVG, SaagMS, Cloud GA (1992):AcontrolIed trialoffluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodcficienc) syndrome. NEnglJMed 326, 793-798.
50. ViIlanuevaMS, QuagliarelloVJ (1996): Prevention and treatment of cryptococcal meningitis in patients with AIDS. CXS Drugs 4, 246 bis 256.
51. McKinsey DS, Kauffman CA, Pappas PG, Cloud GA, Girard vVM, Sharkey PK, Hamill RJ, Thomas CJ, Dismukes vVE and the National Institute of Allergy and Infectious Diseases Mjcoses Study Group (1996): Fluconazole therap) for histoplasmosis. Clm Infect Dis 23, 996-1001.
52. Sharkey-Mathis PK, VelezJ, Fetchick R, GrabillJR (1993): Hisloplasmosis in the acquired immunodeficiency syndrome (AIDS): Treatment with itraconazole and (vuconazove.JAcquiredImmuneDenency Syndrome 6, 809-819.
53. Wheat L, Mawhinney S, Hafner R, McKinsey D.: Fluconazole treatment for histoplasmosis in AIDS: Prospective multicenter noncomparative trial. Abstr. 1233, 34. ICAAC, 1994, Orlando, USA.
54. Pappas PG, Kauffman CA, Perfect JR, Johnson PC, McKinsey DS, Bamberger DM, Hamill R, Sharkey PK, Chapman SvV, Sobel JD (1995): Alopecia associated with fluconazole therapy Ann Inlern Med 123, 354-357.
55. Kauffman CA, Pappas PG, McKinsey DS, Greenfield RA, Perfect JR, Cloud GA, Thomas CJ, Dismukes vVE, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group 1996) Treatment of Lymphocutaneous and Visceral Sporotrichosis with Fluconazole. Clm Infect Dis 22:46-50.
56. Wheat J (1995): Endemic Mycoses in AIDS: a clincal review. Clm MicrobRevS, M 6-159.
57. Penk A, Pittrow L (1997): Seltene Mkosen in der operativen Medizin. In: M)kosen in der operativen Medizin (Hrsg.: Kujath, P). Thieme, Stuttgart-New York (wird publiziert)
58. Anaissie EJ, Kontoyiannis D, Hüls C, Prine R, BossoJA, Bodey GP. Efficacy, safety and pharmacokinetics of high dose fluconazole in patients with fungal infections. Abstr. 626, 32. ICAAC, 1992, Anaheim, USA.
59. Koszyca B, Ellis D, Toogood I, B)ard RvV: Fluconazole in the treatment of pulmonary z)gomycosis. Mycoses 38, 277-280.
60. Diaz M, Negroni R, Montero-Gei F, Castro LGM, Sampaio SAP, Borelli D, Restrepo A, Franco L, Bran JL, Arathoon EG, Stevens DA (1992): A Pan-American 5-) ear study of fluconazole therapy for deep m) coses in the immunocompetent host. Clm Infect Du 14 (Suppl.l), 568-576.
61. Sundar S, Singh VP, Agraval NK, Gibbs DL, Murray HW (1996): Treatment of kala-azarwith oral fluconazole. ianrf/ 348, 614.
62. Pittrow L, Penk A (1997): Plasma and tissue concentrations of fluconazole and their correlation to breakpoints. Mycoses (wird publiziert)
63. Pittrow L, Penk A (1997): Voraussetzungen für eine effektive antim) kotische Therapie bei nicht-neutropenischen Patienten. In: Mykosen in der operativen Medizin (Hrsg: Kujath, P). Thieme, Stuttgart-New York (wird publiziert)
64. Ansari AM, Gould IM, Douglas JG (1990): High dose oral fluconazole for oropharyngeal candidosis in AIDS.C 25, 720-721.
65. Hood S, Denning DvV (1996): Treatment of fungal infection in AIDS.J4C37 (Suppl. B), 71-S5.
66. Mitchell TG, Perfect JR (1995): Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcusneoformans, ClinMicrobiolRev 8, 515-518.
67. Einstein HE, Johnson RH (1993): Coccidioidomvcosis: New aspects of epidemiology and therapy. Clm Infect Dis 16, 349-356.
68. Galgiani JN, Catanzaro A, Cloud GA, HiggsJ, Friedman BA, Larsen RA, Gravbill JR (1993): Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 119, 28-35.
69. Bodey G, Bueltmann B, Duguid vV, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S, Naoe S, Okudaira M, Scevola D, van't Wout J (1992): Fungal infections in cancer patients: An international autopsy survey. EurJ Clm Microbiol Infect Dis 11, 99-109
70. Pfaffenbach B, Donhuijsen K, PahnkeJ, Bug R, Adamek RJ, vVegener M, Ricken D (1994): Systemische Pilzinfektionen bei hämatologischen Xeoplasien. MedKlimk 89, 299-304
71. Duswald KH, Zettl R, LederleJ, Penk A, Pittrow L: High-dose fluconazole 800 mg/day in ICU-patients with candidiasis. 20th International Congress of Chemotherapy, June 29-JuIy 3, 1997, S)dney. Abstract (to be published)
72. Milefchik E, Leal M, Haubrich R, Bozzette S, Tilles J, LeedomJ, McCutchanJA, Larsen RA: A phase II dose escalation trial of high dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis. 4th Conference on Retroviruses and Opportunistic Infections, Januar)' 22-27, 1997, Washington. Abstract 610.
73. Bernstein L, Hsu W, Schliozberg J (1996) High dose fluconazole can be safely administered in AIDS patients with severe oropharyngeal candidiasis: a case report. Ann Allergy 76, 83
74. Kelly SL, Lamb DC, Kelly DE, LoefflerJ, Einsele H (1996): Resistance to fluconazole and amphotericin B in Candida albicans from AIDS patients. Lancet 348, 1523-1524.
75. Pappas PG, Kauffman CA, McKinse) DS, Bradsher RvV, Sharke) PK, Chapman SvV, Greenfield R, Neu man C, Dismukes vVE: Fluconazole for the treatment of blastom)cosis, histoplasmosis and sporotrichosis. 32th Annual IDSA Meeting, October 7-9, 1994, Orlando, Abstract 83.
76. Link H, Maschine) er G, Meer P, Hiddemann vV, Schrappe M, Helmerking M, Adam D: Antimicrobial therapy in febrile neutropenic patients; Results of the prospectée studies of the Paul Ehrlich Society of Chemotherapy. 6th EICON May 2-t, 1996, Leipzig, Abstract 21.
77. Viscoli C, Castagnola E, Fioredda F, Ciravegna B, Barigione G, Terragna A (1991): Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemolher 35, 365 bis 367.
78. Driessen M, Cooper PA, Wainer S, Muuazi F, Hahn D, Gous H, De Villiers FPR (1996): Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospecthe randomized trial. Rdialr Infect DisJ 15, 1107-1112.
79. Fasano C, O'KeeffeJ, Gibbs D (1994): Fluconazole treatment of neonates and infants with severe fungal infections not treatable with com entional agents. EurJ Chn MicrobiolInfect Dis 13, 351-354.
80. Fasano C, O'KeeffeJ, Gibbs D. Fluconazole Treatment of Children with Severe Fungal Infections Not Treatable with Conventional Agents (1994): Ear J Chn Microbiol Infect Dis 13, 344-347.
81. Presterl E, Graninger W and a Multicentre Study Group: Efficacy and safety of fluconazole in the treatment of S)stemic fungal infections in pédiatrie patients. EurJ Clin Microbiol Infect Dis 13, 347 bis 351.
82. KoletarSL, O'GradyNP: Treatment of disseminated histoplasmosis. IXth International Conference on AIDSJune 6-11, 1993, Berlin, Abstract 1391.
83. Rebhn T, Meer A, Albrecht H, Greten H (1994): Disseminated cryptococcosis in a patient with AIDS. Mjcoses 37, 275-279.
84. Pouderly vVG (1992): Therapy for cryptococcal meningitis in patients with AIDS. Chn Infect Dis 14 (Suppl. 1), S54-S59.
85. Sarosi GA, Davies SF (1994): Concise review for primär)-care physicians. Therap) for fungal infections. Majo Clin Proc 69, 1111 bis 1117.
86. Kauffman CA (1996): Role of azoles in antifungal therapy Chn Infect Dis 22 (Suppl. 2), S148-S153.